Arbutus presents preliminary ab-729 and pegylated interferon alfa-2a combination data at the easl congress 2023

Treatment was generally well tolerated with continued hbsag declines in some patients warminster, pa., june 21, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preliminary data from its on-going phase 2a clinical trial evaluating the safety, tolerability and antiviral activity of the combination of ab-729, the company's lead rnai therapeutic, and pegylated interferon alfa-2a (ifn) in patients with chronic hepatitis b virus (chbv) was presented today at the european association for the study of the liver (easl) congress.
ABUS Ratings Summary
ABUS Quant Ranking